Biohaven Pharmaceutical Holding Co Ltd

Biohaven Pharmaceutical — Investor Presentation (October 2019)

67 slides from Biohaven Pharmaceutical's investor presentation, Oct 3, 2019

  1. Slide 1: Biohaven Investor Presentation

    Slide 1: Biohaven Investor Presentation

    NEURO INNOVATION BROAD PIPELINE OF LATE STAGE PRODUCT CANDIDATES NYSE: BHVN © 2019 Biohaven Pharmaceuticals Inc. All rights reserved. Biohaven Investor Presentation October 3, 2019

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 2 This presentation contains forward - looking statements within the meaning of “safe harbor” provisions of The Private Securities Litigation Reform Act of 1995, including: statements about our plans to

  3. Slide 3: Biohaven's Neuroinnovation Portfolio

    Slide 3: Biohaven's Neuroinnovation Portfolio

    Biohaven’s Neuroinnovation Portfolio SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 3 Late Stage Development Pipeline Pre - Clinical CGRP antagonism RIMEGEPANT Phase 3 Zydis ® ODT Acute Migraine COMPLETED RIMEGEPANT Phase 3 Acute Migraine COMPLETED RIMEGEPANT P

  4. Slide 4: Aspire to Achieve

    Slide 4: Aspire to Achieve

    Aspire to Achieve • 3 Marketed drugs by 2021 • Grow while maintaining lean, efficient and high performing culture meeting patient needs growing value SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 4 Goal:

  5. Slide 5: CGRP Platform: Therapies for Migraine

    Slide 5: CGRP Platform: Therapies for Migraine

    CGRP PLATFORM Therapies for Migraine

  6. Slide 6: Rimegepant FDA Mid Cycle Communication Update

    Slide 6: Rimegepant FDA Mid Cycle Communication Update

    SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 6 Rimegepant FDA Mid Cycle Communication Update (October 1, 2019): Rimegepant ODT and Tablet NDAs At this time, there are no major safety concerns identified; we do not anticipate the need for a REMS at this time.

  7. Slide 7: Multiple Formulations to Meet Patient Needs from Acute to Preventive

    Slide 7: Multiple Formulations to Meet Patient Needs from Acute to Preventive

    Multiple Formulations With the Potential to Meet Patient Needs from Acute to Preventive Treatment of Migraine SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 7 NO JECTION™ CGRP Drug Delivery Platform 1. Exclusive World - Wide License with Catalent for use of Zyd

  8. Slide 8: Biohaven Strategy: Oral Agents with Dual-Therapy Action

    Slide 8: Biohaven Strategy: Oral Agents with Dual-Therapy Action

    Biohaven Strategy: Advance Oral Agents with Potential Dual - Therapy Action (Acute and Preventive Tx) ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR PREVENTIVE TREATMENT • Indicated based on headache frequency & headache related impairment, including: • Chronic Migraine (CM)

  9. Slide 9: Rimegepant Value Proposition: One and Done

    Slide 9: Rimegepant Value Proposition: One and Done

    Rimegepant Value Proposition: “One and Done” SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 9 Rapid Pain Relief Zydis ® ODT Durable Benefits through 2 days Placebo - like Tolerability

  10. Slide 10: Rimegepant Clinical Trials Published in NEJM and The Lancet

    Slide 10: Rimegepant Clinical Trials Published in NEJM and The Lancet

    Rimegepant Clinical Trials Published in NEJM and The Lancet Articles SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 10 Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised , phase 3, dou

  11. Slide 11: Rimegepant Zydis ODT Phase 3 Study in Acute Treatment of Migraine

    Slide 11: Rimegepant Zydis ODT Phase 3 Study in Acute Treatment of Migraine

    Rimegepant 75 mg Zydis ® ODT Phase 3 Results: Study 303 in the Acute Treatment of Migraine

  12. Slide 12: Rimegepant ODT Broad Spectrum of Efficacy (Study 303)

    Slide 12: Rimegepant ODT Broad Spectrum of Efficacy (Study 303)

    Rimegepant ODT Broad Spectrum of Efficacy (Study 303) Superiority Over Placebo on 21 Consecutive, Hierarchically - Tested Endpoints SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 12 Favors Placebo Favors Rimegepant 1º Pain freedom, 2 hrs 21.2 10.9 10.4 (6.5, 14

  13. Slide 13: Efficacy Highlights: Early and Sustained Effects with a Single Dose

    Slide 13: Efficacy Highlights: Early and Sustained Effects with a Single Dose

    RIMEGEPANT PHASE 3 – STUDY 303, 75 MG ZYDIS ® ODT SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 13 Efficacy Highlights: Rimegepant Zydis ® ODT Shows Early and Sustained Effects with a Single Dose Pain Relief *60 min *90 min *2 hr *24 hr *48 hr Sustained Sustai

  14. Slide 14: Pain Relief: Early Separation From Placebo

    Slide 14: Pain Relief: Early Separation From Placebo

    RIMEGEPANT PHASE 3 – STUDY 303, 75 MG ZYDIS ® ODT Pain Relief: Rimegepant Zydis ® ODT Shows Early Separation From Placebo Beginning within 15 Minutes and is Statistically Significant by 60 Minutes SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 1. Pain Relief is

  15. Slide 15: Rescue Medication Use

    Slide 15: Rescue Medication Use

    RIMEGEPANT PHASE 3 – STUDY 303, 75 MG ZYDIS ® ODT Rescue Medication Use : Rimegepant Treated Patients Had Lower Use of Rescue Meds and Delayed Time to Use *Data are Kaplan - Meier estimates of Rescue Medicine Use; subjects were censored (not included) at the time of taking rescue medi cation, and th

  16. Slide 16: Safety Profile: Rimegepant 75 mg ODT

    Slide 16: Safety Profile: Rimegepant 75 mg ODT

    RIMEGEPANT PHASE 3 – STUDY 303, 75 MG ZYDIS ® ODT Safety Profile: Rimegepant 75 mg ODT was Well Tolerated and Low Rates of AEs SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 16 • The most common AEs were nausea and urinary tract infection (≤1.6%) • There were n

  17. Slide 17: Pooled Liver Function Test Profile

    Slide 17: Pooled Liver Function Test Profile

    RIMEGEPANT (BHV - 3000) PHASE 3 – 301 , 302 (75 MG TABLET) & 303 (75 MG ZYDIS ® ODT) Pooled Liver Function Test (LFT) Profile: Rimegepant Liver Safety was Similar to Placebo Across Studies ALT or AST Rimegepant N=1771 Placebo N=1785 > ULN 2 48 (2.7%) 52 (2.9%) > 3x ULN 2 (0.1%) 2 (0.1%) > 5x ULN 1 (

  18. Slide 18: Summary: Rimegepant 75 mg ODT Profile

    Slide 18: Summary: Rimegepant 75 mg ODT Profile

    RIMEGEPANT PHASE 3 – STUDY 303, 75 MG ZYDIS ® ODT Summary : Rimegepant 75 mg ODT – Profile of Rapid and Sustained Effect in the Acute Treatment of Migraine SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 18 • Rapid onset of pain relief with single dose • Numeric

  19. Slide 19: Rimegepant Long Term Safety: Study 201 Interim Analysis

    Slide 19: Rimegepant Long Term Safety: Study 201 Interim Analysis

    RIMEGEPANT LONG TERM SAFETY – STUDY 201, INTERIM ANALYSIS 13JUN2 019 SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 19 • 111,573 doses of rimegepant 75 mg administered across 1,798 patients with migraine • Median number of days in study 278 • <3% of subjects di

  20. Slide 20: Long Term Safety Study: Fixed-Dosing Cohort LFT Results

    Slide 20: Long Term Safety Study: Fixed-Dosing Cohort LFT Results

    RIMEGEPANT (BHV - 3000) LONG TERM SAFETY STUDY – STUDY 201, INTER IM ANALYSIS 13JUN2019 SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 20 • Subjects in the 12 - week scheduled every other day plus as needed dosing on alternate days (QOD+PRN) cohort (n=286) were

  21. Slide 21: Study 201 On-Treatment Central Labs LFT Results

    Slide 21: Study 201 On-Treatment Central Labs LFT Results

    RIMEGEPANT LONG TERM SAFETY – STUDY 201, INTERIM ANALYSIS 13JUN2 019, ON - TREATMENT CENTRAL LABS Fixed - Dosing (QOD+PRN) Study 201 Cohort LFT Results ALT or AST Rimegepant N=286 > 3x ULN 0 > 5x ULN 0 > 10x ULN 0 > 20x ULN 0 Total Bilirubin > 2x ULN 0 Alkaline Phosphatase > 2x ULN 0 LFT Results fro

  22. Slide 22: Reduction in Moderate-Severe Migraine Days in Fixed-Dosing Cohort

    Slide 22: Reduction in Moderate-Severe Migraine Days in Fixed-Dosing Cohort

    • 48.4% of subjects in the fixed - dosing QOD+PRN cohort experienced ≥50% reduction from baseline during month 3 in the frequency of monthly migraine days with moderate - to - severe pain intensity RIMEGEPANT LONG TERM SAFETY STUDY – STUDY 201 Rimegepant Fixed - Dosing Cohort Preliminarily Shows Red

  23. Slide 23: Improvement in Migraine-Specific Disability (MIDAS)

    Slide 23: Improvement in Migraine-Specific Disability (MIDAS)

    33.0 20.7 19.1 17.8 17.2 15 20 25 30 35 baseline 12 24 36 52 Mean MIDAS Total Score N=1631 N=1211 N=1085 N=917 N=1789 P<.0001 versus baseline – all time points Time (weeks) *Lower score reflects improvement Improvement in Migraine - Specific Disability after Dosing with Rimegepant 75 mg up to Once D

  24. Slide 24: Rimegepant Reduces Lost Productivity Time

    Slide 24: Rimegepant Reduces Lost Productivity Time

    TIME (weeks) Absenteeism Days of missed work, school, household, social or leisure activities due to migraine P <.0001 vs baseline for all timepoints 17.8 10.7 9.6 8.9 8.9 16.2 10 9.4 8.7 8.4 5 8 11 14 17 20 baseline 12 24 36 52 ABSENTEEISM PRESENTEEISM Presenteeism Days when migraine interfered wit

  25. Slide 25: Improved Health Related Quality of Life Outcomes

    Slide 25: Improved Health Related Quality of Life Outcomes

    Treatment with Rimegepant 75 mg up to Once Daily Improves Outcomes on Health Related Quality of Life ( HRQoL ) 14.5 15.4 17.4 17.6 11.5 12.8 13.7 14.4 15.4 15.8 17 .0 17.2 0 2 4 6 8 10 12 14 16 18 20 0 Weeks 12 Weeks 24 Weeks 36 Weeks 52 Weeks Restrictive Role Preventative Role Emotional Function P<

  26. Slide 26: Prevention Strategy: Treatment Paradigm as a Continuum

    Slide 26: Prevention Strategy: Treatment Paradigm as a Continuum

    Prevention Strategy: Redefine the Treatment Paradigm as a Continuum SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 26 • Rimegepant acute efficacy and durability of action demonstrated in three Phase 3 Trials • Early signals from 201 data and 303 study suggest t

  27. Slide 27: Vazegepant: Third Generation CGRP Receptor Antagonist

    Slide 27: Vazegepant: Third Generation CGRP Receptor Antagonist

    FIRST INTRANASAL FORMULATION OF A SMALL MOLECULE CGRP RECEPTOR A NTAGONIST SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 27 • Superior chemical attributes • Potent antagonist at the human CGRP receptor • Highly soluble and high free fraction • US composition o

  28. Slide 28: CGRP Platform Development Milestones & Next Steps

    Slide 28: CGRP Platform Development Milestones & Next Steps

    CGRP Platform Development Milestones & Next Steps SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 28 2Q19 Initiate a Phase 2 proof of concept trial to evaluate the safety and efficacy of rimegepant in patients with treatment refractory trigeminal neuralgia 2Q19

  29. Slide 29: Rimegepant Commercial & Marketing Update

    Slide 29: Rimegepant Commercial & Marketing Update

    Rimegepant Commercial & Marketing Update

  30. Slide 30: Commercial and Launch Readiness Remain on Timelines

    Slide 30: Commercial and Launch Readiness Remain on Timelines

    SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 30 Biohaven’s Commercial and Launch Readiness Remain on Timelines Region Business Director (RBDs): COMPLETED hires District Business Manager (DBMs): Hires: 50% hire completed, on timelines Neuroscience and Primary

  31. Slide 31: Biohaven's Experienced Commercial Leaders

    Slide 31: Biohaven's Experienced Commercial Leaders

    Biohaven’s Experienced Commercial Leaders Mark Glackin • >30 yrs • Allergan/GSK Adrienne Ross • >30 yrs • BMS Jimi Ayodele • >25 yrs • PWC/Otsuka Chris Barrett • >25 yrs • Schering/BI/DBV Cassi O’Neil • >15 yrs • BMS/AZ/ITV HCP Marketing Chris Deluzio • >20 yrs • BMS/BI/AZ/Takeda Graham Goodrich • >

  32. Slide 32: Managed Markets and National Accounts Team

    Slide 32: Managed Markets and National Accounts Team

    SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 32 Biohaven Managed Markets and National Accounts Team K. Floeder, RPh • 25 years industry experience • 16 years account management Key Accounts • CVS • Aetna G. Tadlock, RPh • 25+ years industry experience • 13 ye

  33. Slide 33: Highly Experienced Region Business Directors

    Slide 33: Highly Experienced Region Business Directors

    33 Bernadette Raymond Industry: 30 yrs RBD: 15 yrs Biohaven’s Highly Experienced Region Business Directors (RBD) Lead National Commercial Sales Efforts Chris Deluzio SVP Sales/ Comm Ops BJ Jones CCO, Migraine & Common Diseases Chad McMahon Industry: 23 yrs RBD: 3 yrs Brian Keenan Industry: 20 yrs RB

  34. Slide 34: Glutamate Platform

    Slide 34: Glutamate Platform

    GLUTAMATE PLATFORM Therapies for Neurologic and Neuropsychiatric Indications

  35. Slide 35: The Role of Glutamate in Brain Synapses

    Slide 35: The Role of Glutamate in Brain Synapses

    NORMAL FUNCTION Healthy State The Role of Glutamate: Present in 90% of Brain Synapses SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 35 EXCITOTOXICITY Diseased State AMYOTROPHIC LATERAL SCLEROSIS SPINOCEREBELLAR ATAXIA DEMENTIA NEURODEGENERATION NEUROTOXICITY S

  36. Slide 36: Glutamate Mechanisms of Action in CNS

    Slide 36: Glutamate Mechanisms of Action in CNS

    Glutamate Mechanisms of Action in CNS SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 36 Glutamate Transporter Modulation • Troriluzole • BHV - 0223 Glutamate NMDA Receptor Antagonism • BHV - 5000 Third - party clinical trials provide basis for exploration of ri

  37. Slide 37: Unmet Medical Need in ALS

    Slide 37: Unmet Medical Need in ALS

    UNMET MEDICAL NEED IN ALS SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 37 Riluzole ( Rilutek ® ) is approved for the treatment of patients with amyotrophic lateral sclerosis (ALS) and proven to extend survival • Originally marketed by Sanofi, received FDA app

  38. Slide 38: Troriluzole: Rational Drug Discovery to Optimize Therapy

    Slide 38: Troriluzole: Rational Drug Discovery to Optimize Therapy

    Troriluzole: Rational Drug Discovery to Optimize Therapy SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 38 • Improved absorption • Enhanced bioavailability • Reduced drug burden • Reduced first pass metabolism • Favorable safety profile • Once - daily dosing

  39. Slide 39: Peptide Transporter Enhances Absorption of Troriluzole

    Slide 39: Peptide Transporter Enhances Absorption of Troriluzole

    Peptide Transporter 1 Enhances Absorption of Troriluzole PepT1 PepT1 = Peptide Transporter 1 ACTIVE ABSORPTION IN INTESTINAL TRACT BY PEPT1 SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 39

  40. Slide 40: Troriluzole: Targeted Lead-Indication Development Strategy

    Slide 40: Troriluzole: Targeted Lead-Indication Development Strategy

    Social Anxiety Disorder Generalized Anxiety Disorder Bipolar Depression Troriluzole: Targeted Lead - Indication Development Strategy SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 40 * = Third - party study / collaboration ongoing or planned (ADCS Collaboration

  41. Slide 41: Troriluzole Phase 2/3 Trial Design: Generalized Anxiety Disorder

    Slide 41: Troriluzole Phase 2/3 Trial Design: Generalized Anxiety Disorder

    TRORILUZOLE (BHV - 4157) PHASE 2/3 TRIAL DESIGN GENERALIZED ANXIETY DISORDER • Chronic or excessive worry, restlessness, fatigue, difficulty concentrating, insomnia • Impairs ability to function socially or at work • Irritable bowel - like gastrointestinal issues • Significant unmet need • GAD has a

  42. Slide 42: Yale POC Study: Anti-Anxiety Effects of BHV-0223

    Slide 42: Yale POC Study: Anti-Anxiety Effects of BHV-0223

    BHV - 0223 DESIGN • Double - blind, placebo controlled crossover trial with two Impromptu Speech Task sessions • Subjects diagnosed with Social Anxiety Disorder • N=22 randomized (21 completed) • BHV - 0223 vs PBO, dosed 1 hour prior to public speaking stress task; separated by two to ten days to al

  43. Slide 43: Riluzole Preclinical Anti-Anxiety Effects

    Slide 43: Riluzole Preclinical Anti-Anxiety Effects

    RILUZOLE PRECLINICAL Yale Human POC Study Is Consistent with Preclinical Models Showing Riluzole’s Anti - Anxiety Effects and Enhancement of Recognition Memory Sugiyama et al 2017 (Brain Behavioral Research) SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 43 Ant

  44. Slide 44: Pathological Features of Alzheimer's Disease

    Slide 44: Pathological Features of Alzheimer's Disease

    Pathological Features of Alzheimer’s Disease • Brain atrophy • Neuronal cell death • Amyloid and tau pathology • Synapse loss (most highly correlated with clinical symptoms) • Glial cell dysfunction Congdon Nat Rev Neurol. 2018;14(7):399 - 415 SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROL

  45. Slide 45: Glutamate Transporter GLT-1 is Reduced in Human AD Brains

    Slide 45: Glutamate Transporter GLT-1 is Reduced in Human AD Brains

    Glutamate Transporter (GLT - 1) is Reduced in Human AD Brains SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 45 Human autopsy observations from AD and controls (n=13) GLT - 1 immunoreactivity in temporal neocortex area in AD is significantly weaker than that in

  46. Slide 46: Riluzole Rescues Symptoms, Function and Pathology in AD Models

    Slide 46: Riluzole Rescues Symptoms, Function and Pathology in AD Models

    Increases GLT - 1 Glutamate Transporter 4 SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 46 Riluzole Rescues Symptoms, Function and Pathology in AD Animal Models 1 Pereira Proc Natl Acad Sci 2014; 2 Hunsberger J Neurochem 2015; 3 Hunsberger, Metab Brain Dis 201

  47. Slide 47: Troriluzole Phase 2/3 Trial Design in Alzheimer's Disease

    Slide 47: Troriluzole Phase 2/3 Trial Design in Alzheimer's Disease

    TRORILUZOLE (BHV - 4157) PHASE 2/3 SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 47 • Key entry criteria • Diagnosis of mild to moderate Alzheimer’s disease with Mini - Mental State Exam (MMSE) score of 14 – 24 • Co - primary efficacy endpoints • Alzheimer's D

  48. Slide 48: Cerebellar Ataxias

    Slide 48: Cerebellar Ataxias

    Cerebellar Ataxias SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 48 • Characterized by: • Poor balance with falls • Dysarthria / dysphagia • Incoordination of limbs • Cognitive impairment • Postural or kinetic tremor • Oculomotor dysfunction • Spinocerebellar

  49. Slide 49: Troriluzole Treated SCA Patients vs Natural History Cohort

    Slide 49: Troriluzole Treated SCA Patients vs Natural History Cohort

    Troriluzole Treated SCA Patients Treated for 1 Year Compared to Matched Ashizawa Natural History Cohort SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 49 • Post - hoc analysis of patients enrolled in long - term extension of Phase 2b/3 troriluzole SCA trial • P

  50. Slide 50: Study BHV4157-206: Randomized Trial of Troriluzole in SCA

    Slide 50: Study BHV4157-206: Randomized Trial of Troriluzole in SCA

    Study BHV4157 - 206: Randomized Controlled Trial of Troriluzole in SCA Key Entry Criteria • SCA genotypes ( SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA10) Design • Sample size: 230 subjects • Randomization: 1:1 • Stratification: by SCA genotype • Dose: Troriluzole 200 mg QD vs. Placebo QD • Primary Outc

  51. Slide 51: Evidence for Glutamatergic Dysfunction in OCD

    Slide 51: Evidence for Glutamatergic Dysfunction in OCD

    Accumulating Evidence for Glutamatergic Dysfunction in OCD SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 51 GENES ANIMAL MODELS NEURAL NETWORKS PATIENTS IN THE CLINIC Genetic association studies: Glutamate transporter gene (SLC1A1 on chromosome 9p24) associate

  52. Slide 52: Neurochemical Evidence for Glutamate Dysregulation in OCD

    Slide 52: Neurochemical Evidence for Glutamate Dysregulation in OCD

    Neurochemical Evidence for Glutamate Dysregulation in OCD SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 52 Rosenberg et al. 2000 Consistent with pathologic hyperactivity in cortico - striatal circuit Suggests clinical testing of agents that enhance glutamate u

  53. Slide 53: Randomized Controlled Trial with Riluzole Augmentation

    Slide 53: Randomized Controlled Trial with Riluzole Augmentation

    Randomized Controlled Trial with Riluzole Augmentation SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 53 • Outpatients with moderate to severe OCD severity (Y - BOCS score ≥ 21) and free of medication treatment for at least six weeks • Randomized to receive flu

  54. Slide 54: Study BHV4157-202: Troriluzole in OCD

    Slide 54: Study BHV4157-202: Troriluzole in OCD

    Study BHV4157 - 202: Randomized Controlled Trial of Troriluzole in OCD KEY ENTRY CRITERIA • Moderate to severe OCD and inadequate response to standard of care DESIGN • Sample size: 226 subjects • Randomization: 1:1 • Dose: Troriluzole 200 mg QD vs. Placebo QD (in patients on standard of care) • Prim

  55. Slide 55: BHV-0223 Optimized to Address Riluzole Delivery Limitations for ALS

    Slide 55: BHV-0223 Optimized to Address Riluzole Delivery Limitations for ALS

    BHV - 0223 SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 55 • Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that causes muscle weakness, difficulties with breathing and swallowing, and death • Generic riluzole has been proven t

  56. Slide 56: BHV-0223 Phase 1 Single Dose PK Results

    Slide 56: BHV-0223 Phase 1 Single Dose PK Results

    BHV - 0223 BHV - 0223 Phase 1 Single Dose PK Results SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 56 Observations • (A) Sublingual (SL) 35 mg dose of BHV - 0223 vs. 50 mg dose of oral Rilutek ( riluzole ) • (B) SL 40 mg BHV - 0223 vs. 50 mg Rilutek • BHV - 02

  57. Slide 57: BHV-5000: A Novel Low-Trapping NMDA Antagonist

    Slide 57: BHV-5000: A Novel Low-Trapping NMDA Antagonist

    BHV - 5000 SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 57 • Potential first - in - class, next - generation NMDA receptor antagonist • Exclusive license from AstraZeneca • Low - trapping agent • Orally bioavailable prodrug of the IV drug lanicemine • NMDA mo

  58. Slide 58: Glutamate Platform Development Milestones & Next Steps

    Slide 58: Glutamate Platform Development Milestones & Next Steps

    Glutamate Platform Development Milestones & Next Steps SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 58 3Q2019 Complete Response Received, ongoing discussions with FDA for BHV - 0223 NDA for treatment of ALS via 505(b)(2) 4Q2019 Futility analysis expected in P

  59. Slide 59: MPO Platform

    Slide 59: MPO Platform

    MPO PLATFORM Therapies for Neuroinflammation

  60. Slide 60: BHV-3241 for Neuroinflammation: Multiple System Atrophy

    Slide 60: BHV-3241 for Neuroinflammation: Multiple System Atrophy

    BHV - 3241 FOR NEUROINFLAMMATION SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 60 • Rare, rapidly progressive and fatal neurodegenerative disease • Prevalence: 2 – 5 per 100,000 • Clinical symptoms • Parkinsonism: characteristic tremor (not responsive to L - D

  61. Slide 61: BHV-3241 Background

    Slide 61: BHV-3241 Background

    BHV - 3241 FOR NEUROINFLAMMATION SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 61 BHV - 3241 Background • Myeloperoxidase (MPO) enzyme • Key mediator of oxidative and inflammatory processes that lead to neurodegeneration • Promotes alpha - synuclein aggregatio

  62. Slide 62: Neuroprotective Effects of BHV-3241 in MSA Animal Model

    Slide 62: Neuroprotective Effects of BHV-3241 in MSA Animal Model

    BHV - 3241 FOR NEUROINFLAMMATION SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 62 Neuroprotective Effects of BHV - 3241 in MSA Animal Model 1 Reduces GCIs of alpha - synuclein Promotes functional (motor) improvements Suppresses microglial activation RLZ treate

  63. Slide 63: BHV-3241 Clinical Experience

    Slide 63: BHV-3241 Clinical Experience

    BHV - 3241 FOR NEUROINFLAMMATION SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 63 • Studied in approximately 250 subjects (healthy volunteers, Parkinson’s disease, MSA) • Generally safe and well tolerated • Demonstrated target engagement ( ↓ blood MPO activity

  64. Slide 64: Phase 2 Study in MSA Completed by AstraZeneca

    Slide 64: Phase 2 Study in MSA Completed by AstraZeneca

    BHV - 3241 FOR NEUROINFLAMMATION SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 64 • Phase 2 study: randomized double - blind controlled trial • N=61 subjects (MSA - C, 34; MSA - P, 24) • Randomized to 12 weeks treatment • Placebo BID vs BHV - 3241 300 mg BID v

  65. Slide 65: Plan for Phase 3 Study of BHV-3241 in MSA

    Slide 65: Plan for Phase 3 Study of BHV-3241 in MSA

    BHV - 3241 FOR NEUROINFLAMMATION SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 65 DESIGN • Sample size: 252 subjects • Randomization: 1:1 • Dose: 600 mg BID vs. Placebo *based on Ph2 • Primary outcome measure: Unified MSA Rating Scale • Sites: US & EU (UK, FR,

  66. Slide 66: MPO Platform Development Milestones & Next Steps

    Slide 66: MPO Platform Development Milestones & Next Steps

    SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 66 MPO Platform Development Milestones & Next Steps Received Orphan Disease designation from FDA On track to Initiate a Phase 3 clinical trial for the treatment of MSA, a rare, rapidly progressive and fatal neuroin

  67. Slide 67: Thank You!

    Slide 67: Thank You!

    Thank You! www.biohavenpharma.com Zydis ® is a registered trademark of Catalent. Rilutek ® is a registered trademark of Covis Pharma B.V. NYSE: BHVN © 2019 Biohaven Pharmaceuticals Inc. All rights reserved.

Source: SEC EDGAR · 8-K filed Oct 3, 2019

More decks from Biohaven Pharmaceutical Holding Co Ltd